Unlock the Surrogates
Current methods of diagnosing and monitoring glaucoma sometimes fail physicians and patients alike – could molecular biomarkers open the door to better outcomes?
Rajendra S. Apte |
The importance of adequate monitoring and management of glaucoma needs no reinforcement. Glaucoma-related death of retinal ganglion cells (RGCs) cannot be reversed: early diagnosis is therefore critical, as without timely detection, therapeutic intervention may be too late to prevent permanent vision loss. Yet our options for screening and monitoring the progression of this disease, particularly in its early stages, are profoundly unsatisfactory – and glaucoma remains one of the leading causes of blindness worldwide. How might we resolve this situation? In my view, development of molecular biomarkers – quantifiable surrogates of disease progression and therapeutic response – could transform the management of this most problematic disease.
Enjoy our FREE content!
Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!
Login if you already created an account
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine